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Summary Osteoblasts are bone-forming cells that differentiate from mesenchymal stem cells.
Differentiation processes are coordinately and dynamically controlled in the mesenchymal cells
by specific signal transduction pathways. Bone morphogenetic proteins (BMPs), members of the
TGF-b superfamily, induce not only bone formation in vivo, but also osteoblast differentiation of
mesenchymal cells in vitro. BMP signals are transduced from plasma membrane receptors to the
nucleus through both Smad-dependent and -independent pathways, and are regulated by many
extracellular and intercellular proteins that interact with BMPs or components of BMP signaling
pathways. To understand the molecular mechanisms underlying the role of BMPs in osteoblast
differentiation, it is important to elucidate the BMP signaling transduction pathways that are
active during osteoblast differentiation. In this review, we summarize the BMP signaling pathways
that are known to function in osteoblast development. We also describe our recent findings
regarding the molecular mechanisms underlying the cross-talk between BMP/Smad and NF-kB
pathways in osteoblast differentiation.
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Despite its hard structure, bone actually exists in a constant
state of dynamic turnover known as bone remodeling in order
to maintain bone volume and calcium homeostasis through-
out life [1,2]. At remodeling sites, osteoblasts lay down new
bone, while osteoclasts resorb existing bone. Osteoblasts
produce bone matrix proteins such as type I collagen, the
most abundant (90%) extracellular matrix protein in bone.
The remaining 10% is composed of a large number of non-
collagenous proteins, e.g., osteonectin, osteocalcin, bone
sialoprotein and various proteoglycans. Non-collagenous pro-
teins participate in the process of matrix maturation or
mineralization, and may regulate the functional activity of
bone cells [1,2]. Osteoblasts, chondrocytes, myocytes and
adipocytes all derive from a common progenitor known as the
mesenchymal stem cell [3,4]. During the process of differ-
entiation, progenitor cells acquire specific phenotypes under
the control of respective regulatory factors [1—4].
Bone morphogenetic proteins (BMPs), members of the
transforming growth factor b (TGF-b) superfamily, were
originally identified by their ability to induce ectopic bone
formation when implanted into muscle tissue [5,6]. BMPs are
involved in nearly all processes associated with skeletal
morphogenesis and play pivotal roles in the regulatory sig-
naling network. BMP signals are transduced from plasma
membrane receptors to the nucleus through both Smad-
dependent and -independent pathways, and are regulated
by many extracellular and intracellular molecules that inter-
act with BMPs or components of BMP signaling pathways. The
unique and specific ability of BMPs to induce bone formation
was expected to be useful for the development of bone
regeneration treatments; however, BMPs cannot generate
enough of a clinical response to be used in this context
[7—9]. A possible reason might be that inflammatory cyto-
kines inhibit the bone formation and osteoblast differentia-
tion induced by BMPs. For example, one inflammatory
cytokine, tumor necrosis factor (TNF) a, inhibits osteoblast
differentiation in multiple models, including fetal calvaria,
bone marrow stromal cells and MC3T3-E1 cells [10—12].
Inflammatory cytokines such as TNFa and interleukin (IL)-
1 are produced primarily by activated macrophages, but are
also produced by many other structural cell types, including
fibroblasts, smooth muscle cells and osteoblasts [13,14]. The
binding of these cytokines to their receptors results in the
activation of an inflammatory response that is classically
mediated by a broad variety of pro-inflammatory cytokines,
including interleukins, interferon-g and chemokines [13,14].
In addition, intracellular signal transduction pathways acti-
vated by these cytokines elicit a wide spectrum of othercellular responses. These responses include the modulation
of differentiation and proliferation in multiple cell types, and
the induction of apoptosis via several signaling pathways,
such as meiosis-specific serine/threonine protein kinase
(MEK), extracellular signal-regulated kinase (ERK), c-Jun
N-terminal kinase (JNK), p38 kinase and NF-kB [14].
Among these intracellular molecules, the signal transduc-
tion stimulated by TNFa and IL-1 occurs partly through the
activity of the NF-kB family of transcription factors [15,16].
In this pathway, the activated NF-kB, mainly p50 and p65
heterodimers, enters the nucleus and binds to NF-kB-respon-
sive elements to regulate the expression of genes that are
involved in the regulation of immune and inflammatory
responses, proliferation, tumorigenesis and survival [15,16].
In contrast to NF-kB, BMP signaling provides anti-prolifera-
tive differentiation signals to osteoblasts as well as other
tissues [17]. Furthermore, BMP, acting through both Smad-
dependent and -independent mechanisms, inhibits the cell
cycle and increases apoptosis by regulating pro-apoptotic
proteins [18,19]. Together, there seem to be antagonistic
effects between BMP/Smad and NF-kB signaling systems.
Therefore, in this review, we will first summarize the role of
BMPsignaling inosteoblast differentiation and thendiscuss the
molecularmechanisms underlying TNFa/NF-kB-mediated reg-
ulation of BMP-2-induced osteoblast differentiation.
2. Regulation of osteoblast differentiation
Bone consists of hydroxyapatite crystals and various extra-
cellular matrix proteins, including type I collagen, osteocal-
cin, osteopontin, bone sialoprotein and proteoglycans. Most
of these bone matrix proteins are secreted and deposited by
mature osteoblasts, which are aligned on the bone surface.
The formation of hydroxyapatite crystals in osteoid is also
regulated by osteoblasts [20—22]. Expression of a number of
bone-related extracellular matrix proteins, high alkaline
phosphatase (ALP) enzymatic activity and responsiveness
to osteotropic hormones and cytokines are believed to be
major characteristics of osteoblasts.
During embryogenesis, bone tissues are formed through
two distinct pathways: intramembranous ossification and
endochondral ossification. In the case of intramembranous
ossification, osteoblasts differentiate directly frommesench-
ymal cell considensations, whereas in the case of endochon-
dral ossification, the condensed mesenchymal cells
differentiate into chondrocytes and form a cartilaginous
template. Then the surrounding mesenchymal cells immedi-
ately differentiate into osteoblasts after maturation of
hypertropic chondrocytes in the template suggesting that
osteoblasts and chondrocytes are derived from a common
Figure 1 A schematic model for differentiation of a mesenchymal stem cell into tissue specific cells by specific transcriptional
factors. A mesenchymal stem cells can differentiate into osteoblasts, chondrocytes, myoblasts, and adipocytes. Each differentiation
program is regulated by specific transcription factors: Runx2/Osterix, Sox5/6/9, MyoD family and PPARg, respectively.
BMP signaling in osteoblast differentiation 35progenitor cell (Fig. 1). Furthermore, it is well known that
osteoblasts, chondrocytes, adipocytes, myoblasts, tendon
cells, and fibroblasts differentiate from the common pre-
cursor of bone marrow mesenchymal stem cells [4,5,23]. The
lineages are determined by different transcription factors.
The transcription factors Runx2, Osterix and b-catenin reg-
ulate osteoblast differentiation, Sox family proteins (Sox9,
Sox5 and Sox6) regulate chondrocyte differentiation, MyoD
transcription factors (MyoD, Myf5 and Myogenin) regulate
myogenic differentiation, and C/EBP family (C/EBPb, C/EBPd
and C/EBPa) and PPARg transcription factors regulate adi-
pocyte differentiation (Fig. 1). Runx2 first directs multipo-
tent mesenchymal cells to a preosteoblastic state, after
which b-catenin, Osterix and Runx2 together convert the
cells into mature osteoblasts [4,5,23].
Several cytokines and hormones, such as BMP, TGFb, Wnt,
hedgehog, fibroblast growth factors and estrogen, are
involved in the regulation of mesenchymal cell differentia-
tion by stimulating intracellular signaling pathways. Among
them, BMP is one of the most powerful inducers of ectopic
bone formation and strongly promotes differentiation of
mesenchymal cells into osteoblasts [4,5,23].
3. The BMP/Smad signaling pathway
3.1. BMP ligands
BMPs are members of the TGF-b superfamily that were
originally identified by their ability to induce ectopic bone
formation when implanted into muscle tissue [5]. Subse-
quently, several cDNAs encoding proteins capable of ectopic
bone formation were isolated and more than 15 BMP genes
have now been identified in vertebrates [6]. Several recom-
binant BMP proteins have been shown to induce ectopic bone
formation [5,24]. BMPs are translated as large preproproteins
containing signal peptides. Proproteins undergo dimeriza-
tion, after which specific proteolytic enzymes cleave the
dimerized proprotein to generate biologically active dimeric
mature proteins. It has been shown that some BMP hetero-
dimers are more potent in inducing ectopic bone formation
than their respective homodimers [5,24].Although most BMPs are expressed in a variety of tissues
during embryogenesis, some are detected in only a restricted
set of tissues after birth. In adult mice, BMP-3, BMP-4, BMP-5
and BMP-6 are highly expressed in lung, whereas BMP-7 is
highly expressed in kidney. The expression levels of BMP-4
and BMP-6 are much higher in adults than in young mice.
Osteoblasts are an important source of BMPs in bone matrix,
and expression of some BMP mRNAs is induced during bone
formation. BMP-4 is transiently induced in callus-forming
cells in the early phase of fracture healing. BMP-6 is highly
expressed in hypertrophic chondrocytes, which are inter-
mediate between cartilage and bone during endochondral
ossification [24,25].
3.2. BMP receptors
Signaling by TGF-b superfamily members, including BMPs, is
generally initiated upon their binding to transmembrane
receptors. BMPs bind to two major types of membrane-bound
serine/threoninekinasereceptors, type I and type II receptors.
BMPR-IA (ALK-3), BMPR-IB (ALK-6) and ActR-IA (ALK2) are BMP
type I receptors. Constitutively active ALK1 has been shown to
phosphorylate BMP-regulated Smads, suggesting that ALK1 is
also BMP type I receptor. Individual BMP ligands bind to dif-
ferent type I receptors in different cell types. In general, type
II BMP receptors show lower ligand binding ability and lower
ligand specificity than those of type I receptors. ActR-II and
ActR-IIB binds to BMP-2 and BMP-4 at least in in vitro [24,25].
The type II receptor, BMPR-II, binds exclusively to BMP ligands,
including BMP-2, BMP-4, BMP-6, BMP-7, GDF-5 and GDF-9.
ActR-II and ActR-IIB, originally identified as activin receptors,
can also act as receptors for BMP-6, BMP-7 and GDF-5. BMP
receptor oligomerization appears to be different from activin
and TGF-b receptor oligomerization. For activin and TGF-b
receptors, the ligands first bind to type II receptors, which in
turn leads to the recruitment of type I receptors. However, it
has been demonstrated that BMPR-II and type I receptors form
both homomeric and heteromeric complexes, even before
ligand stimulation [24,25].
BMPR-IA is more widely expressed than BMPR-IB among
tissues, but BMPR-IB is the only receptor expressed in all
36 E. Jimi et al.types of cartilage. Expression of the dominant-negative form
of BMPR-IB, but not dominant-negative BMPR-IA, blocks
chondrogenesis and osteogenic differentiation. ALK2 is
expressed in isolated chick osteoblasts and chondrocytes,
and overexpression of constitutively active ALK2 enhances
chondrocyte maturation, suggesting that it may be essential
for normal chondrocyte maturation and skeletal develop-
ment [24,25].
3.3. BMP intracellular signal transduction
Smad proteins play central roles in intracellular signaling by
members of the TGF-b superfamily. Upon binding of a BMP
ligand, the type II receptor transphosphorylates the type I
receptor at an intracellular juxtamembrane site termed the
GS domain. The phosphorylated type I receptor, in turn,
phosphorylates a set of intracellular substrate signaling pro-
teins collectively known as Smads. Smad proteins are classi-
fied into three subgroups, i.e., receptor-regulated Smads (R-
Smads), a common-partner Smad (Co-Smad) and inhibitory
Smads (I-Smads). The BMP-specific R-Smads, Smad1, Smad5,
and Smad8 are phosphorylated by the BMP type I receptors at
their carboxy-terminal Ser-Ser-X-Ser motifs. The phosphory-
lated Smad proteins form complexes with the Co-Smad,
Smad4, translocate into the nucleus, bind to the regulatory
elements of target genes, and regulate their transcription
(Fig. 2) [5,24,25].
Smads are critically involved in osteoblast differentiation.
Smad1 and Smad5 have been shown to be the major signaling
molecules for inducing differentiation of myoblastic C2C12
cells into osteoblasts. Smad1 and Smad5, but not Smad8,
synergize with Smad4 to promote chondrocyte differentia-
tion from chondroprogenitor cells. By contrast, Smad8 and
Smad4 exhibit modest effects in mesenchymal cells.
Smad1 and Smad5, but not Smad8, are activated by BMP-6
and BMP-7 [26], whereas Smad1, Smad5 and Smad8 are all
activated by BMP-2 [27]. Non-Smad signaling mediated byFigure 2 A schematic model for BMP signal transduction. Signali
transmembrane receptors, which are serine/threonine kinases. The
Smad4. The complex translocates into nucleus and associates with ot
the target genes.several kinases, including mitogen-activated protein (MAP)
kinases p38, ERK and Jun N-terminal kinase (JNK), and
phosphoinositol-3 (PI3) kinase, is also activated by BMP
receptors and regulates cell differentiation [24,25].
3.4. Role of BMPs in osteoblast differentiation in
vitro and in vivo
In order to examine the molecular mechanisms underlying
ectopic bone-induction, the biological effects of recombi-
nant BMP proteins on osteoblast differentiation have been
studied in vitro using cell lines and primary cells. In cultures
of osteoblast lineage cells, various BMPs induce the expres-
sion of ALP, parathyroid hormone (PTH)/PTH-related protein
receptor, type I collagen and osteocalcin [28]. BMPs also
stimulated the formation of mineralized bone-like nodules
in these cells. BMPs can also induce osteoblast differentiation
in several other types of cell in culture as well as some
pluripotent cell lines [28]. C3H10T1/2 clone 8, a cell line
established from a C3H mouse embryo, differentiates into
myoblasts, adipocytes and chondrocytes in the presence of 5-
azacytidine [29,30]. BMP-2 and BMP-4 induce osteoblastic
differentiation of C3H10T1/2 cells [30—33].
BMPs were originally identified as an activity that induces
ectopic bone formation in muscular tissue, suggesting that
BMPs regulate the pathway of differentiation of myogenic
cells. While examining this possibility, Katagiri et al. found
that BMP-2 inhibited myogenic differentiation of a mouse
myoblast cell line, C2C12, and instead diverted their differ-
entiation pathway into that of osteoblasts [34]. TGF-b also
inhibited myogenic differentiation of C2C12 cells, but failed
to induce osteoblast differentiation [34]. This system has
been widely used to examine the role of BMP signaling in
osteoblast differentiation [3,24—26].
Smad transcription factors are substrates of activated
type I receptor kinases in the cytoplasm. The phosphorylated
Smad proteins translocate into the nucleus, bind to theng of BMPs is initiated upon their binding to type I and type II
type I receptors phosphorylate Smad1/5/8 from a complex with
her DNA-binding proteins, and then regulates the transcription of
BMP signaling in osteoblast differentiation 37regulatory regions of target genes and regulate their tran-
scription [4,5,24,25]. Thus, Smad proteins are key molecules
in the transduction of signals from the cell membrane to the
nucleus. Overexpression of Smad1, Smad5 or Smad8 induces
ALP activity and osteocalcin production in C2C12 and 10T1/2
cells [35]. Smad4 is a Co-Smad that cooperates with all R-
Smads. By contrast, both Smad6 and Smad7 inhibit signal
transduction of the all TGF-b superfamily members. Smad
signals are regulated positively and negatively not only by
other Smads but also by transcriptional activators and/or
repressors [3,5,24,25].
Although BMP is known to be one of the most powerful
cytokines to induce ectopic bone formation and strongly
promotes differentiation of mesenchymal cells into osteo-
blasts and chondrocytes [24—26], until recently, it was
still unknown whether BMP was really important for bone
formation in physiological and pathological conditions,
because mice lacking BMP-2 or BMP-4 die at early embryonic
stages. However, mice often offer a unique opportunity to
combine genetic and biochemical studies of skeletal
growth and patterning. So far, at least 150 mouse loci are
known that affect various aspects of skeletal morphogen-
esis. The mouse ‘‘short ear’’ gene is required for normal
growth and patterning of skeletal structures, and for repair
of bone fractures in adults. Kingsley et al. [36] showed that
the short ear region contains the gene for BMP-5 that is
deleted or rearranged in several independent mutations at
the short ear locus. Furthermore, mutations in Gdf-5 gene,
another member of the TGF-b superfamily, are known to be
responsible for the skeletal abnormalities observed in the
classical mouse mutation, brachypodism, which are char-
acterized by skeletal abnormalities restricted to the limbs
and limb joints [37]. The skeletal elements of BMP-6 defi-
cient mice are indistinguishable from wild-type. BMP-7-
deficient mice also have skeletal patterning defects
restricted to the rib cage, the skull, and the hindlimbs
[38,39]. The BMP-4/7 double heterozygotes develop minor
defects in two restricted areas of the skeleton, the rib cage,
and the distal part of the limbs, suggesting that Bmp-4 and
Bmp-7 act in the same pathway to assure proper guidance of
mesenchymal condensations of the ribs extending toward
the sternum [40]. Inactivation of the Gdf-6 gene causes
defects in joint, ligament, and cartilage formation at sites
distinct from those seen in Gdf-5 mutants, including the
wrist and ankle, the middle ear, and the coronal suture
between bones in the skull [41]. Mice lacking both Gdf-5 and
Gdf-6 show additional defects, including severe reduction
or loss of some skeletal elements in the limb, additional
fusions between skeletal structures, scoliosis, and altered
cartilage in the intervertebral joints of the spinal column
[41]. Homozygous mutant mice carrying a targeted
deletion of Gdf-11 exhibit anteriorly directed homeotic
transformations throughout the axial skeleton and posterior
displacement of the hindlimbs [42]. The transgenic mice
overexpressing the dominant-negative form of BMP type I
receptor, which is necessary for BMP signaling, were gen-
erated [43]. The mice exhibited a severe reduction in bone
formation, indicating an important role for BMP signaling in
bone development [43]. By contrast, Bmp-3-deficient mice
have twice as much trabecular bone as wild-type, indicating
that BMP-3, the most abundant BMP in adult bone, is a
negative determinant of bone density [44].The mutations of BMP signaling have been identified in
humans with heritable skeletal abnormalities. A mutation in
human cartilage-derived morphogenetic protein (CDMP-1) is
associated with a recessive human chondrodysplasia (acro-
mesomelic chondrodysplasia, Hunter-Thompson type) [45].
The disorder, characterized by skeletal abnormalities
restricted to the limbs and limb joints, is phenotypically
similar to murine brachypodism, which is due to mutations
in Gdf-5, the mouse homologue of hCDMP-1. By contrast,
mutations in the human noggin gene and those in GDF/CDMP1
leading to its hyperactivation results in symphalangism [46].
Recently, mutations in the ALK2 gene have been identified in
individuals with fibrodysplasia ossificans progressiva (FOP)
[47—49]. These findings indicate that BMPs are key molecules
of differentiation of osteoblasts and chondrocytes from
mesenchymal progenitor cells during skeletal development.
BMP induces Runx2 expression in mesenchymal progeni-
tors in a Smad-dependent fashion. Runx2 interacts with
Smad1 and Smad5, and regulates the expression of target
genes which are involved in osteoblast differentiation [50—
54]. However, several molecules inhibit this signaling cas-
cade, thereby suppressing osteoblast differentiation. For
example, Smad6 negatively controls osteoblast differentia-
tion as an inhibitory Smad [53]. Yoshida et al. showed that
Tob, a member of the emerging family of anti-proliferative
proteins, inhibits Smad1, Smad5 and Smad8, and conse-
quently suppresses osteoblast differentiation. Furthermore,
Tob-deficient mice showed greater bone mass resulting from
increased numbers of osteoblasts [54]. Therefore, these
inhibitory network systems also contribute to the differen-
tiation of mesenchymal cells into osteoblasts.
3.5. Role of Runx2 and Osterix in osteoblast
differentiation
Since Runx2-deficient mice have no bone tissue or osteo-
blasts, this transcription factor appears to be indispensable
for osteoblast differentiation. Runx2 has also been identi-
fied as a gene responsible for cleidocranial dysplasia (CCD),
an autosomal-dominant disease with abnormalities in the
bone formed by intramembranous ossification. BMP-2 mark-
edly upregulates the expression of Runx2 through the acti-
vation of Smad signaling [53,55,56]. Furthermore, Smad1
and Smad5 physically interact with Runx2 and enhance its
transcriptional and osteoblastogenic activity [50,53]. The
importance of this interaction was supported by a genetic
report showing that mutations in Runx2 that delete the
Smad-binding domain result in CCD [51]. Further evidence
has established the significance of the BMP—Smad—Runx2 in
osteoblast differentiation. As expected, Runx2-deficient
mice show severely impaired osteoblast differentiation,
but no abnormalities in the patterning of the skeleton.
Although the overexpression of Runx2 promotes osteoblas-
tic differentiation of mesenchymal cells [57], osteopenia
and frequent bone fractures are observed in transgenic
mice overexpressing Runx2 specifically in bone tissue
[58]. Therefore, Runx2 appears to inhibit bone formation
at the late stage.
In addition to Smad and Runx2, C/EBP family proteins,
which play a key role in the adipocyte differentiation of
mesenchymal cells, also regulate osteoblast differentiation.
C/EBPb and C/EBPd associate with Runx2 and increase osteo-
38 E. Jimi et al.calcin promoter activity [59], and C/EBPb promotes osteo-
blast differentiation in association with Runx2 [60], providing
a novel role for the C/EBP family in bone metabolism.
Another transcription factor, Osterix, was originally iden-
tified as a gene that was markedly upregulated by BMP-2
stimulation [61]. Like the Runx2 knockout mice, Osterix-
deficient mice showed a complete absence of bone formation
and osteoblasts, indicating that Osterix is also essential for
bone development and osteoblastogenesis [61]. In these
mice, Runx2 is still expressed in the mesenchymal cells,
but Osterix is not expressed in the mesenchymal cells of
Runx2-deficient mice [61]. These data suggest that Runx2 is
an upstream transcription factor for Osterix. Furthermore,
Osterix binds to NFATc1 (NFTA2) or NFATc2 (NAFT1) and
increases the promoter activity of Col1a1 [62]. However,
the target genes of Osterix are currently unknown. Identifi-
cation of these target genes will provide new areas for
exploring the molecular mechanisms of osteoblast biology.
4. Inflammatory cytokines suppress
osteoblast differentiation
Inflammatory cytokines contribute to local and systemic bone
loss in inflammatory bone diseases such as rheumatoid arthri-
tis and periodontitis as well as in estrogen deficiency [63—
65]. In patients with rheumatoid arthritis, TNFa and other
cytokines are overproduced in inflamed joints by various cells
that infiltrate the synovial membrane [65]. Anti-TNF drugs
such as infliximab, etanercept and adalimumab have been
shown to not only diminish signs and symptoms of disease, but
also to prevent joint damage [66]. Under these conditions,
osteoblast-mediated bone formation cannot compensate for
accelerated osteoclastic bone resorption, suggesting a direct
inhibitory effect of TNFa on osteoblasts. Further support for
this inhibitory effect was provided by TNFa transgenic mice,
which exhibit well-characterized features of rheumatoid
arthritis and develop symptoms of general osteoporosis,
including a reduction of trabecular bone in the metaphysis
[67]. In addition, osteoblastic cells derived from TNFa trans-
genic mice form significantly fewer and smaller nodulesFigure 3 Schematic representation of NF-kB proteins family of pr
number of amino acids in each protein is indicated on the right. Presu
acid 433) are shown. RHD: Rel homology domain, NLS: nuclear local
zipper, GRH: glycine rich hinge.under basal conditions and in the presence of BMP-2, again
indicating that TNFa reduces osteoblast function.
Consistent with clinical and in vivo animal studies, the
inhibitory effects of TNFa on bone formation in vitro were
first reported in 1987 using a neonatal rat calvarial organ
culture system [10]. Subsequent studies demonstrated that
TNFa blocks osteoblast differentiation in multiple models,
including fetal calvaria, bone marrow stromal cells and
MC3T3-E1 cells [11,12]. TNFa inhibited not only spontaneous
osteoblast differentiation, but also BMP-induced osteoblast
differentiation via Smad-dependent or -independent
mechanisms [52]. TNFa inhibited the BMP-2-induced expres-
sion of Runx2, osteocalcin and ALP activity in C2C12 cells in a
dose-dependent manner. TNFa also inhibited the phosphor-
ylation of Smad1/5/8 by inducing Smad6, an inhibitory Smad
[68]. These responses were mediated via several signaling
pathways, including MEK, ERK, JNK, p38 and NF-kB [14]. Our
studies have focused on NF-kB signals, because BMP and NF-
kB have opposite biological functions during inflammatory
processes [15,16,18,19].
5. The NF-kB signaling pathway
The NF-kB/Rel family of ubiquitously expressed transcription
factors consists of five members in mammals: p65 (RelA), c-
Rel, RelB, NF-kB1 (p50/p105) and NF-kB2(p52/p100) [15,16].
All five members share an N-terminal domain of 300 amino
acids, designated the Rel homology domain (RHD), which is
responsible for DNA binding, dimerization and interaction
with the inhibitory IkB proteins. Three members, p65, c-Rel
and RelB, contain C-terminal transcriptional activation
domains (TAD) that are crucial for their ability to induce
target gene expression, while homodimers of p50 and p52
lack TADs and therefore have no intrinsic ability to drive
transcription. p65, c-Rel and RelB are synthesized as mature
proteins, whereas p50 and p52 are first synthesized as longer
precursors, p105 and p100, respectively, which are then
processed to their smaller forms by the proteasome (Fig. 3).
NF-kB activity is controlled by shuttling from the cyto-
plasm to the nucleus in response to cell stimulation. Inoteins. Members of the NF-kB proteins families are shown. The
med sites of cleavage for p100 (amino acid 447) and p105 (amino
ization signal, TA: transcriptional activation domain, LZ: leucine
BMP signaling in osteoblast differentiation 39unstimulated cells, NF-kB is predominantly localized in the
cytoplasm in a complex with several inhibitory IkB proteins,
including IkBa, IkBb, IkBe and IkBg. The IkB proteins are
characterized by the presence of five to seven ankyrin
repeats that are essential for their interaction with NF-kB
proteins. In response to a variety of stimuli, such as TNFa or
IL-1b, IkBs are phosphorylated (Ser32 and Ser36 for IkBa and
Ser19 and Ser21 for IkBb) by the activated IkB kinase (IKK)
complex, leading to their ubiquitination and degradation by
the 26S proteasome. This process, which is a key step in the
regulation of the NF-kB pathway, allows NF-kB dimers to
translocate to the nucleus, where they induce the expression
of target genes (Fig. 4) [15,16].
The IKK complex consists of two catalytic kinase subunits,
IKKa (IKK1) and IKKb (IKK2), and a regulatory subunit, NEMO
(NF-kB essential modulator), also called IKKg [15,16]. IKKa
and IKKb share 52% amino acid homology and have similar
functional domains, including an N-terminal catalytic
domain, a centrally positioned leucine-zipper motif that is
involved in homo- and heterodimer formation, and a C-
terminal helix-loop-helix (HLH) domain. NEMO/IKKg inter-
acts with a C-terminal region of IKKb, designated the NEMO
binding domain (NBD), which is critical for the formation of
the IKK complex [69]. Although NEMO/IKKg has no catalytic
function, it is indispensable for signal-dependent NF-kB acti-
vation. IKKb is mainly required for the canonical NF-kB
pathway that depends on IkB degradation. Despite the struc-
tural similarity of IKKa and IKKb, biological and geneticFigure 4 Two different NF-kB signaling pathways. The classi-
cal (canonical) pathway (left) is activated by a large number of
agonists, such as TNFa, IL-1, LPS, or TCR. Activation of this
pathway depends on the IKK complex (IKKa/b and NEMO), which
phosphorylates IkBa (Ser32, 36) to induce rapid degradation.
This pathway is essential for immune responses, inflammation,
tumorgenesis and cell survival. The alternative (non-canonical)
pathway (right) is activated by a limited number of agonists
which are involved in secondary lymphoid organogenesis,
mature B cell function and adaptive immunity. This pathway
requires NIK and IKKa, which induce the slow processing of p52
from p100, resulting in dimerization and activation of the p52/
Rel B heterodimer.studies indicate that IKKb is the dominant kinase involved
in IkBs phosphorylation. On the other hand, IKKa provides a
partially redundant role in stimulus-induced NF-kB activa-
tion. Recent studies have shown that IKKa is involved in an
alternative (non-canonical) NF-kB pathway that regulates
the RelB/p52 dimer [15,16]. In unstimulated cells, RelB is
retained in the cytoplasm as a RelB-p100 precursor complex,
which prevents RelB-mediated transcriptional activity. Upon
stimulation, the IkB-like C-terminal domain of p100 is pro-
teolyzed, releasing RelB-p52 dimers that translocate to the
nucleus. This non-canonical NF-kB pathway is induced in
response to only a few members of the TNF family, including
B cell-activating factor (BAFF), CD40 ligand and lymphotoxin
b (LTb), and is mostly involved in lymphoid organ develop-
ment (Fig. 4) [15,16].
6. The role of NF-kB signaling in BMP-2-
induced osteoblast differentiation
The transcription factor NF-kB has a key role in inflammation
and immune responses [15,16]. NF-kB signaling may be asso-
ciated with metabolic diseases such as cachexia and diabetes
[70,71]. Inhibition of IKKb-specific peptides suppresses
inflammatory bone loss by inhibiting osteoclastogenesis in
an arthritis model, suggesting that NF-kB is a major target of
inflammatory bone diseases [72,73]. Although the involve-
ment of NF-kB in osteoclastogenesis has been well investi-
gated, little is currently known about the possible
involvement of NF-kB in osteoblast differentiation, espe-
cially the cross-talk between BMP/Smad and NF-kB signaling
in osteoblast differentiation.
Eliseev et al. reported that inhibition of NF-kB by over-
expression of a dominant-negative form of IkBa (IkBaDN)
leads to the induction of osteoblast differentiation [74].
Osteosarcoma Saos2 cells overexpressing IkBaDN (Saos2-
IkBaDN) exhibit higher expression of osteoblast phenotypic
genes such as ALP, Runx2 and osteocalcin, and are more
responsive to BMP-2 relative to wild-type cells (Saos2-wt)
or empty vector-infected controls (Saos2-EV). Furthermore,
BMP-2 signaling and Smad phosphorylation are significantly
increased in Saos2-IkBaDN cells in comparison to Saos2-EV
cells. Inhibition of NF-kB signaling in Saos2-IkBaDN cells is
associated with decreased expression of the BMP signaling
inhibitor Smad7, suggesting that in osteosarcoma Saos2 cells,
NF-kB represses BMP/Smad signaling and BMP-2-induced dif-
ferentiation through Smad7 [74].
The role of TNFa-induced NF-kB activation in BMP-2-
induced osteoblast differentiation has also been examined.
Blocking the activation of NF-kB by TNFa using the cell
permeable NF-kB activation antagonist TAT-NBD prevented
TNFa from suppressing TGFb-stimulated Smad luciferase
activity, BMP-2-induced Runx2 mRNA expression and osteo-
blast differentiation in MC3T3-E1 cells. By contrast, an inac-
tive mutant (MUT-TAT-NBD) had no effect. These results
indicated that inhibition of NF-kB could suppress the anti-
osteoblastogenic activity of TNFa and relieve the suppression
of BMP-2-induced Runx2 expression mediated by TNFa [75].
We also showed that NF-kB is involved in the inhibitory
effect of TNFa on BMP-2-induced osteoblast differentia-
tion. Inhibition of BMP-2-induced Id1-luciferase activity
coincides with the activation of NF-kB in p65/ mouse
embryonic fibroblasts (MEFs) in a p65 dose-dependent
Figure 5 A model of NF-kB-mediated inhibition of BMP/Smad-
mediated DNA-binding activity. NF-kB, particularly the p65 sub-
unit, binds the Smad1/Smad4 complex directly or indirectly, and
that this binding interferes with the DNA binding of Smad
proteins induced by BMP-2.
40 E. Jimi et al.manner. Overexpression of p65 completely abrogated the
Id1-luciferase activity induced by the constitutively active
form of Smad1 and Smad4. TNFa inhibited BMP-induced
DNA binding of Smad proteins in wild-type MEFs, whereas
TNFa failed to inhibit DNA binding in p65/ MEFs. The
pharmacological NF-kB inhibitor mentioned above restored
the inhibitory effects of TNFa on both BMP-induced DNA
binding of Smad proteins and ALP activity. This study
suggests that NF-kB, particularly the p65 subunit, binds
the Smad1/Smad4 complex directly or indirectly, and that
this binding interferes with the DNA binding of Smad
proteins induced by BMP-2 (Fig. 5, [76]).
Consistent with these results, time- and stage-specific
inhibition of endogenous IKKb in differentiated osteoblasts
substantially increases trabecular bone mass and bone
mineral density without affecting osteoclast activities in
mice [77]. Inhibition of the IKKb-NF-kB axis maintains bone
formation, thereby preventing osteoporotic bone loss
induced by ovariectomy in adult mice, and enhances the
expression of Fos-related antigen (Fra-1), an essential tran-
scription factor involved in bone matrix. These results
strongly suggest that targeting IKKb-NF-kB may help to
promote bone formation in the treatment of osteoporosis
and other inflammatory bone diseases [77].
7. Conclusion
Since the discovery of BMP in 1965, it has been expected to
serve as a powerful agent of osteoanagenesis. Notably, BMP
can potently induce ectopic bone when matrix is implanted
into muscular tissue in rodents [5]; however, BMPs did not
produce the desired results in either basic research with
primates or at the clinical level [7—9].
The effects of BMPs are modulated by extracellular BMP
antagonists, including noggin, chordin, follistatin, which
block BMP signaling by binding to BMPs and preventing theirassociation with specific cell surface receptors. Downstream
effectors of BMP signaling, the Smad proteins, are also
regulated by protein degradation via the ubiquitin-protea-
some system. Smurf1 and Smurf2 are Smad-specific E3 ubi-
quitin ligases that selectively interact with BMP receptor-
activated Smads [24,25]. Future identification of proteins
that enhance rather than inhibit BMP/Smad signaling during
osteoblast differentiation will prove a significant advance to
the field.
Recently, we and another group revealed that the inhibi-
tory effect of TNFa on BMP signaling in osteoblast differen-
tiation is closely linked to the NF-kB pathway [72,73]. NF-kB
activation inhibits osteoblast differentiation at least in part
by interfering with Smad signaling. Smads 1/5/8 are gener-
ally accepted as very early downstream effectors in the BMP
signaling pathway, and are thus fundamental for osteoblastic
differentiation in response to BMP ligands [24,25]. An intra-
cellular balance of signal intensities between NF-kB and
BMP/Smad is therefore crucial for osteoblast differentiation,
and might also inform future bone regeneration applications.
Furthermore, modulation of Smad activity may be useful for
establishing new approaches for the treatment of a variety of
bone and cartilage disorders.
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